Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Antitumor activity of Ono-4007 related to TNF induction

April 7, 1997

CAT and Techniclone to initiate trials for tumor therapy

March 27, 1997

Bristol-Myers Squibb discovers new ribosome-inactivating protein

March 27, 1997

Multikine trial approved in Israel

March 21, 1997

Immunogen terminates Oncolysin development

March 20, 1997

Cel-Sci purchases complete rights to Multikine

March 11, 1997

AltaRex receives funding for clinical trials on Ovarex

March 10, 1997

IDEC and Roche submit applications for IDEC-C2B8

March 5, 1997

ONYX expands ONYX-015 clinical trials

March 4, 1997

Roche's Roferon-A receives EU approval

March 4, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...